No CYP-interactions.

Antiviral neuramidinase inhibitor used perorally (up to 75 mg x 2 daily for 5 days) in symptomatic influenza in adults and children > 1 year, and as prevention after viral exposure in individuals > 13 years. About 90% of the absorbed dose is metabolzed by liver esterases, the carboxylated metabolite excreted in urine. CYPs are not involved in the biotransformation.

Uneventful use reported in 2 patients with acute porphyria.